Corindus Vascular Robotics (Formerly known as Corindus)
309 Waverley Oaks Road
123 articles with Corindus Vascular Robotics (Formerly known as Corindus)
Corindus Announces New Clinical Data Showing 20 Percent Reduction in Patient Radiation Exposure with Robotic-assisted Intervention
Clinical evidence shows significant patient radiation reduction with CorPath® GRX Vascular Robotic System
Neuroradiologist in Toronto Performs World’s First Robotic-Assisted Aneurysm Coiling Using Corindus Technology
Novel procedure marks a pivotal step in implementation of robotics to address neurovascular disease
Corindus to Showcase CorPath® GRX System at Transcatheter Cardiovascular Therapeutics 2019 Conference
Breakfast symposium and conference activities to highlight capabilities of vascular robotic technology and advancements in automation and remote treatment
First-in-Human Telerobotic Coronary Intervention Procedures Published in The Lancet Journal, EClinicalMedicine
Renowned medical journal publishes the successful clinical results of remote PCI procedures using CorPath® GRX Robotic System technology
Corindus Vascular Robotics, Inc., a leading developer of precision vascular robotics, reported financial results for its second quarter ended June 30, 2019.
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Corindus Vascular Robotics, Inc. (NYSE: CVRS) on Behalf of Corindus Shareholders and Encourages Corindus Investors to Contact the Firm
Pursuant to the proposed transaction, announced on August 8, 2019 and valued at $1.1 billion, Corindus shareholders will receive $4.28 in cash for each share of Corindus common stock owned.
Corindus Vascular Robotics announced that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG.
Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer, and David Long, Chief Financial Officer, will present at the Canaccord Genuity 39th Annual Growth Conference as follows:
Corindus Vascular Robotics, Inc. announced that it will release second quarter 2019 financial and business results on Thursday, August 8, 2019 before the open of the U.S. financial markets.
One of the nation’s largest hospital networks adopts vascular robotic technology in multiple hospital locations to treat patients in need of cardiovascular care
Corindus Announces Regulatory Approval of CorPath GRX for Neurovascular Intervention in Australia and New Zealand
Expanded indication provides access to robotic technology in vascular procedures from head to toe
Corindus Vascular Robotics, Inc., a leading developer of precision vascular robotics, announced that the Company will join the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1.
Corindus CorPath GRX System Successfully Used in Live Complex Robotic-Assisted Coronary Intervention at EuroPCR 2019
Case broadcast live to thousands of EuroPCR attendees from Clinique Pasteur in France
Company will highlight CorPath GRX capabilities in complex vascular procedures
Corindus to Present “Evolution of Robotics: Automation, Remote Applications, and Beyond” at SCAI 2019 Breakfast Symposium on May 21, 2019
Company to feature latest milestones and technology advancements in vascular robotics at SCAI 2019
Eleven purchase orders for CorPath GRX Systems as adoption grows
Chesapeake Regional Medical Center installs CorPath® GRX Vascular Robotic Systems in all catheterization labs
Corindus Vascular Robotics, Inc. announced that it will release first quarter 2019 financial and business results on Tuesday, May 7, 2019 after the close of the U.S. financial markets.
Japan represents one of the largest markets for PCI globally, with over 1,200 hospitals performing nearly 250,000 PCI procedures annually
Corindus Vascular Robotics Files Required Registration Statement for Holders of Recently Completed $19.8 Million Private Placement
Shares sold in private placement are subject to contractual six-month lock-up